Antiretroviral Agents and Prevention of Malaria in HIV-Infected Ugandan Children | Zendy

Jane Achan | Zendy; Abel Kakuru | Zendy; Gloria Ikilezi | Zendy; Theodore Ruel | Zendy; Tamara D. Clark | Zendy; Christian Nsanzabana | Zendy; Edwin D. Charlebois | Zendy; Francesca Aweeka | Zendy; Grant Dorsey | Zendy; Philip J. Rosenthal | Zendy; Diane V. Havlir | Zendy; Moses R. Kamya | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiretroviral Agents and Prevention of Malaria in HIV-Infected Ugandan Children

Author(s) -

Jane Achan,

Abel Kakuru,

Gloria Ikilezi,

Theodore Ruel,

Tamara D. Clark,

Christian Nsanzabana,

Edwin D. Charlebois,

Francesca Aweeka,

Grant Dorsey,

Philip J. Rosenthal,

Diane V. Havlir,

Moses R. Kamya

Publication year - 2012

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1200501

Subject(s) - lopinavir , ritonavir , medicine , lumefantrine , regimen , artemether/lumefantrine , lopinavir/ritonavir , malaria , artemether , hazard ratio , incidence (geometry) , confidence interval , virology , plasmodium falciparum , immunology , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy , artemisinin , physics , optics

Human immunodeficiency virus (HIV) protease inhibitors show activity against Plasmodium falciparum in vitro. We hypothesized that the incidence of malaria in HIV-infected children would be lower among children receiving lopinavir-ritonavir-based antiretroviral therapy (ART) than among those receiving nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based ART.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research